#2658 In >870k adults with T2DM or obesity, GLP-1 receptor agonists showed no increase in autoimmune or inflammatory disease risk, and were instead linked to lower mortality, heart failure, stroke and dementia. Excellent real-world safety signals. @RheumNow #ACR25

Abst 2694: Post-hoc analysis of Phase 2 PAISLEY SLE trial examined impact of deucravacitinib on renal dysfunction 🔹 Plasma proteins a/w ↑ BILAG renal score and ↓ UPCR --> reduced by WK 32 🔹 Biomarkers inversely related to eGFR were reduced with deucra vs PBO @RheumNow #ACR25 https://t.co/6CvmQ9lCfS

• https://x.com/AkhilSoodMD/status/1983576311118389425/photo/1
• https://x.com/AkhilSoodMD/status/1983576311118389425/photo/1

Lots of interest in MRI for GCA diagnosis... but what about monitoring? Case series of 14 pts: MRI identified relapse prior to symptoms or inflammatory markers in 2 cases, including those on TCZ, which hides them More available in US context, noninvasive, & more structures https://t.co/pnrI9SEpll

• https://x.com/EBRheum/status/1983575532861083696/photo/1

This prospective study from Brazil evaluated the effect of RHZ vax in SSc pts SSc pts had ⬆️rates of seroconversion mean titers ⬆️ from BL Local rxs ⬇️ in SSc pts Systemic rxns comparable among the 2 grps interesting data. longterm studies still needed #ACR25 @RheumNow Abs2653 https://t.co/wJqpPrAHKG

• https://x.com/RHEUMarampa/status/1983559370366664781/photo/1
• https://x.com/RHEUMarampa/status/1983559370366664781/photo/1
• https://x.com/RHEUMarampa/status/1983559370366664781/photo/1

Thank you @drdavidliew & @DrLauraCoates ❤️ for highlighting our work. Super-responders (some were IS-Free) do exist with rituximab in #SLE Abstr#1525 @RheumNow https://t.co/S4mMAYInfT

• https://twitter.com/drdavidliew/status/1983555936657854811

Year in Preview SLE: 52% subtherapeutic on weight based HCQ dosing Precision prescribing needed, more so for CKD @RheumNow #ACR25 Abstract 1722 https://t.co/8WqorQ1xJx

• https://x.com/JihaRheum/status/1983555467344310342/photo/1

Hydroxychloroquine in SLE is all about the sweet spot. Not too hot with retinopathy, not too cold with flares, just right by the levels. Yet drug concentrations and TDM are not commonplace in many places - time for change Laura Coates in the #ACR25 meeting review @RheumNow https://t.co/oB3ecfSQQc

• https://x.com/drdavidliew/status/1983555247269404896/photo/1

ACR25 coming to a close with Clinical Year in Preview For PsA, can biologics prevent damage? If so, which one? Difficult to answer often b/c confounding by indication. NLP-informed propensity matching beyond demographics for clinical factors like BSA @RheumNow #ACR25 A#2689 https://t.co/jjpb0kTo34

• https://x.com/JihaRheum/status/1983551740202095038/photo/1

In a U.S. axSpA cohort (n=4,799), women had a 24% higher adjusted risk of TNFi discontinuation vs men especially under age 65. No sex differences seen for IL-17i or JAKi, though sample sizes were small. Highlights need for sex-informed treatment strategies. Abstract#2634 https://t.co/58Dw3nFCsf

• https://x.com/synovialjoints/status/1983549391203119443/photo/1

Fukui et al. CorEvitas study. 12076 RA patients. Propensity score matching. Kidney dysfunction (eGFR<60) reduced chance of CDAI remission (HR 0.71) or remission/LDA (HR 0.88) @RheumNow #ACR25 Abstr#2640 https://t.co/uvTjOQlGD7

• https://x.com/RichardPAConway/status/1983549389504135603/photo/1

Sjögren’s: two Phase 3 RCTs (NEPTUNUS-1 [QM], -2 [Q3M]) test Ianalumab (BAFF/BAFF-R) vs placebo. ΔESSDAI at 48wk: Ianalumab QM > PBO, statistically significant But ΔESSDAI ≈ 0.5–1 pt (vs PBO) below MCII (≥ 3) Promising biology, modest clinical gain #ACR25 @RheumNow LB24 https://t.co/8y580ch9iJ

• https://x.com/JihaRheum/status/1983543847151100285/photo/1

Grader-Beck et al. Ianalumab in Sjogren's disease. NEPTUNUS 1 and 2 studies. 779 patients. Met primary endpoint ESSDAI. Big placebo effect also. Patient and physician global also improved. @RheumNow #ACR25 Abstr#LB24 https://t.co/klhxXW4Jfh

• https://x.com/RichardPAConway/status/1983541078667260247/photo/1

REGULATE RA SBT-77-701 Engineered Treg cell in Refractory RA population 6patients Safety and tolerability: No DLT, CRS or ICANS Efficacy Reduction >50% in TJC and SJC 67% reduction of DAS-CRP >=2 stained up to wk 24 Impressive in pts for whom it works, yet a couple seem to https://t.co/lQAQABPhg0

• https://x.com/AurelieRheumo/status/1983539634459074639/photo/1
• https://x.com/AurelieRheumo/status/1983539634459074639/photo/1
• https://x.com/AurelieRheumo/status/1983539634459074639/photo/1

Kohler et al. Phase 1 study autologous CAR-Tregs in refractory RA. No lymphodepletion needed! 6 participants. 2 doses, second cohort with higher dose better and more sustained response. No CRS or other toxicities. @RheumNow #ACR25 Abstr#LB023 https://t.co/nWva2R7WOQ

• https://x.com/RichardPAConway/status/1983538058684403805/photo/1

#ACR25 Abstr#LB23 Phase 1 trial in 5 refractory #RA of SBT777101, a novel autologous CAR-Treg (without the need for lymphodepletion) showed promising efficacy and safety signal. No DLT, CRS or ICANS. Looking forward to larger data and in other RMDs @RheumNow https://t.co/YyGMSHjA3z

• https://x.com/Yuz6Yusof/status/1983537965545685387/photo/1
• https://x.com/Yuz6Yusof/status/1983537965545685387/photo/1